| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Eli Lilly outlays $3.35bn for secretive drug discovery pact with China's InnoCare | ||
| Do | Australia starts investigation into OpenAI Medicare breach | ||
| Do | Enveda nabs $311m to progress nature-derived drug pipeline | ||
| Do | Genialis and Inventia to enhance pancreatic cancer treatment testing | ||
| Do | Basecamp Research secures $140m for AI-driven therapies | ||
| Mi | European big pharma unites amid 'ringing alarm bells' of continent's dominance | ||
| Mi | Boehringer and Envisagenics to develop precision cancer therapies in $1bn deal | ||
| Mi | BoomRay and Novartis Pharma sign $900m deal for radioligand therapy | ||
| Mi | Boehringer and Envisagenics to develop precision cancer therapies | ||
| Di | Novo targets blockbuster-heavy 2030 but share slump signals unease | ||
| Di | Made Scientific acquires cell therapy facility in Pennsylvania, US | ||
| Di | EC approves Menarini and NewAmsterdam's obicetrapib therapies | ||
| Mo | Beijing unveils blueprint for biomedical dominance by 2030 | ||
| Mo | Telix to acquire ITM in deal worth up to $2.35bn | ||
| Mo | Sandoz and mAbxience agree on emicizumab biosimilar partnership | ||
| 18.09. | FDA approves first gene therapy for Sanfilippo syndrome type A | ||
| 18.09. | Novo targets oral macrocycles with $1.4bn Orbis partnership | ||
| 18.09. | Ona Therapeutics to develop ADC with WuXi's payload-linker platform | ||
| 18.09. | Roche agrees $1bn deal with Dualitas for bispecific antibody research | ||
| 17.09. | Novo taps Anthropic's Claude to 'supercharge' R&D efforts | ||
| 17.09. | Cellares and GenomeFrontier to assess automated GF-CART01 production | ||
| 17.09. | Viatris' Wakix receives Japanese approval to treat OSAS and narcolepsy | ||
| 16.09. | Sling ropes in $123m for oral thyroid eye disease drug | ||
| 16.09. | Gilead and PAHO agree to expedite lenacapavir access for HIV prevention | ||
| 16.09. | Eli Lilly and QurCan sign genetic medicine deal |